Home>Topics>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. GSK's new chairman Hampton to take charge in May

    Headlines

    Thu, 26 Feb 2015

    LONDON, Feb 26 (Reuters) - GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, marking an earlier transition than initially anticipated.

  2. GSK set to complete $20 billion Novartis asset swap next week

    Headlines

    Wed, 25 Feb 2015

    LONDON (Reuters) - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in obtaining clearances for the deal.

  3. GSK set to complete $20 bln Novartis asset swap next week

    Headlines

    Wed, 25 Feb 2015

    LONDON, Feb 25 (Reuters) - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in...

  4. UPDATE 1-Novartis AG wins approval to buy GSK cancer drugs, with conditions

    Headlines

    Mon, 23 Feb 2015

    WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline 's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday.

  5. Canada competition bureau approves GlaxoSmithKline /Novartis deal

    Headlines

    Mon, 23 Feb 2015

    OTTAWA, Feb 23 (Reuters) - Canada's Competition Bureau on Monday approved a deal between GlaxoSmithKline PLC and Novartis AG, noting in a statement that U.S. authorities had already said the transaction could go ahead.

  6. CORRECTED-Novartis AG wins approval to buy GSK cancer drugs with conditions

    Headlines

    Mon, 23 Feb 2015

    WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline 's oncology drugs with conditions, the Federal Trade Commission said on Monday.

  7. Australian regulator says will not oppose GSK , Novartis deals

    Headlines

    Thu, 19 Feb 2015

    SYDNEY, Feb 20 (Reuters) - Australia's competition regulator said on Friday it will not oppose a three part deal between Novartis and GlaxoSmithKline to trade more than $20 billion worth of assets, following approval from EU regulators.

  8. BRIEF- Glaxosmithkline acquires rest of Glycovaxyn

    Headlines

    Wed, 11 Feb 2015

    * GSK press release: gsk strengthens early stage vaccine pipeline with acquisition of Glycovaxyn AG

  9. Aptar's Niche Focus Delivers Profits

    Headlines

    Mon, 9 Feb 2015

    with the recovery in the injectables market following inventory destocking by customers in recent quarters. Now that GlaxoSmithKline 's Flonase allergy treatment is being sold over the counter in the U.S., Aptar should benefit from higher volume

  10. Aptar's Food & Beverage, Beauty & Home Businesses Weighed on 4Q Results; Maintaining $70 FVE

    Commentary

    Fri, 6 Feb 2015

    with the recovery in the injectables market following inventory destocking by customers in recent quarters. Now that GlaxoSmithKline 's Flonase allergy treatment is being sold over the counter in the U.S., Aptar should benefit from higher volumes

« Prev12345Next »
Content Partners